The global red biotechnology market reached a valuation of USD 531.66 billion in 2024, with a projected CAGR of 10.31% from 2025 to 2034, driven by distinct segment-level growth patterns across product types, end-users, and therapeutic applications. Biopharmaceuticals—particularly monoclonal antibodies, recombinant proteins, and gene therapies—represent the largest revenue segment, fueled by their expanding role in treating chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. Vaccines, another critical component of red biotech, are experiencing renewed momentum due to advancements in mRNA tec